Altimmune, Inc. Common Stock

ALT XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

560M

Short interest (May 15)

19.4%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.26%

↓ 5.6%

Available Shares

↓ 64.1%

Price Chart

Company Overview

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001326190

Asset Type: CS

Market Data

Market Cap: $563,975,046

Employees: 57

Status: Active

Short Interest

Current Borrow Fee 0.26%

Range: 0.25% - 0.26%

Available Shares 2M

Range: 1.9M - 2M

Recent Changes

Fee Change: ↑ 2.1%

Available Change: ↓ 4.8%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime